Loading quotes...
Forecast
There is no analyst data available for this company.
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Daiichi Sankyo: Enhertu significantly improves progression-free survival in HER2‑mutated NSCLC
In the phase‑3 DESTINY‑Lung04 trial, Enhertu as first‑line therapy for HER2‑mutated non‑small‑cell lung cancer showed a significantly longer progression‑free survival (median 14.3 vs. 8.3 months) and reduced the risk of progression or death by 37% (HR 0.63) versus pembrolizumab plus chemotherapy. The objective response rate was 70% versus 44.5%, with median duration of response 13.4 versus 9.7 months. The safety profile was consistent with prior knowledge; treatment‑related grade‑3 events occurred in 34.1%, and interstitial lung disease/pneumonitis in 20.8% with four grade‑5 cases. » More on de.investing.com
Daiichi Sankyo rises after partner Merck reports positive study result
Daiichi Sankyo’s shares gained 6.1% after Merck, in partnership with Moderna, reported positive results for a personalized skin cancer vaccine in a late-stage trial. Daiichi was not directly involved in that specific study but benefited from improved sentiment toward Merck, Moderna and their global partners. The price increase helped lift the Nikkei 225 and highlights Daiichi’s sensitivity as a leading Japanese developer of cancer therapies to industry news. » More on de.investing.com
Daiichi Sankyo: CHMP recommends approval of Enhertu for HER2-positive solid tumors
The CHMP of the EMA has recommended approval of Enhertu (trastuzumab deruxtecan) for adult patients with inoperable or metastatic HER2-positive solid tumors. The recommendation is based on three phase II studies showing confirmed objective response rates of about 47–52% and a median duration of response of 5.5 to 14.2 months. The safety profile was consistent with earlier trials; neutropenia, anemia and pneumonic events were observed. The final decision now rests with the European Commission. » More on de.investing.com
Daiichi Sankyo exceeds EPS forecasts significantly thanks to oncology growth
Daiichi Sankyo reported Q4 earnings per share of 70.02 JPY versus a forecast of 55.37 JPY, a positive surprise of 26.46%. Quarterly revenue was 589.71 billion JPY, slightly above expectations; the stock rose 2.04% after the results. Strong growth in the oncology segment, notably driven by ENHERTU, propelled the performance; fiscal-year revenue increased by 12.6%, while operating profit declined due to special items. For 2026 the company expects further oncology growth and additional milestone payments but remains exposed to risks such as supply-chain disruptions and higher costs. » More on de.investing.com
Daiichi Sankyo expands 'One DS Culture' to a distributed global model to sustain oncology momentum
Daiichi Sankyo is consolidating its global transformation around a "One DS Culture," shifting to a distributed global structure that empowers regional autonomy while maintaining a unified corporate identity. The company emphasizes in-house R&D and long-term innovation in antibody‑drug conjugates as the core growth strategy, promoting merit-based, science-driven decision making. Leadership development, clear decision criteria and encouraging proactive "spillover" behaviors are being used to preserve agility and drive continued global expansion in oncology. » More on forbes.com
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 3.32bn | 15.15% |
| Gross profit | 2.64bn | 32.95% |
| Net profit | 473.02m | 81.31% |
| EBITDA | 731.25m | 64.75% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €29.75bn |
Number of shares | 1.82bn |
52-week high/low | €22.26 - €13.60 |
Dividend yield | 2.62% |
Dividends TTM | €0.43 |
Next dividend | €0.28 |
Beta | 0.80 |
P/E ratio | 18.74 |
PEG ratio | 7.90 |
P/B ratio | 3.03 |
P/S ratio | 2.26 |
Company profile
Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.
| Name | Daiichi Sankyo |
| CEO | Hiroyuki Okuzawa |
| Headquarters | Tokyo,
ty Japan |
| Website | |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| IPO | 04/01/2000 |
| Employees | 20,171 |
Ticker symbols
| Exchange | Symbol |
|---|---|
Pnk | DSKYF |
Japan Exchange Group | 4568.T |
Frankfurt | D4S.F |
DĂĽsseldorf | D4S.DU |
MĂĽnchen | D4S.MU |